Lung Cancer

Low-dose chest CT screening is a U.S. standard of care for people at high risk for lung cancer and has a favorable benefit-harm balance when implemented with appropriate selection, follow-up, and management of detected abnormalities. ScienceDirect+1ScienceDirectExecutive Summary: Screening for Lung Cancer: Chest Guideline and Expert Panel Report - ScienceDirectScienceDirectScreening for Lung Cancer: CHEST Guideline and Expert Panel Report - ScienceDirect The USPSTF 2021 recommendation described screening adults aged 50 to 80 years. JAMAJAMAScreening for Lung Cancer | Guidelines

Do not substitute chest radiography for low-dose CT. The practical next step after an abnormal screening CT is risk-stratified diagnostic evaluation within a program able to coordinate repeat imaging, tissue diagnosis, thoracic surgery, radiation oncology, and smoking-cessation support; the supplied sources do not provide a nodule-management threshold or interval algorithm. ScienceDirect+1ScienceDirectExecutive Summary: Screening for Lung Cancer: Chest Guideline and Expert Panel Report - ScienceDirectScienceDirectScreening for Lung Cancer: CHEST Guideline and Expert Panel Report - ScienceDirect

A suspicious lung mass should be biopsied. Bronchoscopy is used for lesions reachable from or adjacent to the airway; CT-guided transthoracic needle biopsy is an alternative when bronchoscopy cannot access the lesion. BMJ+1BMJNon-small cell lung cancerNatureLung Cancer Types, Stages 1 to 4, How It’s Diagnosed, and Genetic Testing | Memorial Sloan Kettering Cancer Center When mediastinal nodes are present, mediastinal sampling can simultaneously establish diagnosis and refine regional stage. BMJBMJNon-small cell lung cancer

Pathology must first distinguish NSCLC from SCLC because their natural history and initial treatment pathways differ. NSCLC comprises more than 80% of lung cancers and includes adenocarcinoma, squamous cell carcinoma, and large-cell carcinoma; SCLC is an aggressive neuroendocrine malignancy and commonly presents with metastatic disease. BMJ+1BMJSmall cell lung cancer - Symptoms, diagnosis and treatmentBMJNon-small cell lung cancer

For NSCLC, plan tissue acquisition with the downstream molecular workflow in mind. Tumor genomic profiling may use tumor, blood, or both; clinically relevant alterations discussed in the supplied sources include EGFR, KRAS, ALK, BRAF, HER2, NTRK, MET, RET, and ROS1. PD-L1 testing informs potential use of immune checkpoint inhibition. NatureNatureLung Cancer Types, Stages 1 to 4, How It’s Diagnosed, and Genetic Testing | Memorial Sloan Kettering Cancer Center The supplied sources do not support a specific universal testing panel, assay, turnaround target, or liquid-biopsy-only diagnostic strategy.

NSCLC staging requires assessment of thoracic primary disease, regional nodes, and distant metastases. The supplied clinical review identifies CT, PET, and mediastinal sampling as core staging investigations for determining local-regional extent and evaluating metastatic disease. BMJBMJNon-small cell lung cancer Stage II and III NSCLC being considered for curative treatment should undergo brain imaging because occult brain metastases alter management. BMJBMJLung cancer: diagnosis and management: summary of ...

Treatment planning should be multidisciplinary before resection, definitive radiation, or concurrent chemoradiation. Operability is not synonymous with anatomic resectability: cardiopulmonary reserve, frailty, performance status, comorbidity, and patient priorities may redirect otherwise localized disease toward stereotactic body radiotherapy (SBRT) or other nonoperative approaches. BMJ+1BMJNon-small cell lung cancerScienceDirectManagement of Patients With Early-Stage Non-Small Cell Lung Cancer: An American College of Chest Physicians Clinical Practice Guideline - ScienceDirect

For stage I NSCLC in average- or low-operative-risk patients, surgical resection remains the preferred treatment; minimally invasive surgery is preferred over thoracotomy. For peripheral tumors 2 cm or smaller, sublobar resection had equivalent overall survival to lobectomy in the evidence synthesized by the CHEST guideline, provided systematic intraoperative hilar and mediastinal nodal sampling or dissection is performed. ScienceDirectScienceDirectManagement of Patients With Early-Stage Non-Small Cell Lung Cancer: An American College of Chest Physicians Clinical Practice Guideline - ScienceDirect SBRT is preferred for stage I NSCLC when surgery is not appropriate. ScienceDirectScienceDirectManagement of Patients With Early-Stage Non-Small Cell Lung Cancer: An American College of Chest Physicians Clinical Practice Guideline - ScienceDirect

For advanced NSCLC, systemic treatment selection depends on histology, molecular genotype, comorbidities, and suitability for immunotherapy or targeted therapy. BMJBMJNon-small cell lung cancer Driver alterations can identify patients for molecularly targeted therapy; the supplied sources specifically identify EGFR, KRAS, ALK, BRAF, HER2, NTRK, MET, RET, and ROS1 as clinically relevant genomic targets and identify PD-L1 as a biomarker used to guide checkpoint-inhibitor treatment. NatureNatureLung Cancer Types, Stages 1 to 4, How It’s Diagnosed, and Genetic Testing | Memorial Sloan Kettering Cancer Center

The supplied search results establish that contemporary professional guidance distinguishes metastatic NSCLC with driver alterations from disease without driver alterations, but they do not provide sufficiently current, source-supported U.S. agent-specific regimens, doses, sequencing, or contraindication thresholds. Use current FDA labeling and living specialty guidelines at the point of prescribing. BMJ+1BMJNon-small cell lung cancerESMOClinical Practice Guideline: Oncogene-Addicted Metastatic Non-Small-Cell Lung Cancer

For extensive-stage SCLC, platinum-etoposide chemotherapy remains foundational. In IMpower133, adding atezolizumab to carboplatin-etoposide improved median overall survival from 10.3 to 12.3 months (hazard ratio for death 0.70, 95% CI 0.54-0.91) and median progression-free survival from 4.3 to 5.2 months (hazard ratio 0.77, 95% CI 0.62-0.96). BMJBMJA phase II, single arm study of CarbopLatin plus Etoposide ... The trial regimen used four 21-day induction cycles followed by atezolizumab maintenance; this is trial evidence rather than a complete current U.S. prescribing algorithm. BMJBMJA phase II, single arm study of CarbopLatin plus Etoposide ...

Lung cancer and its treatment commonly produce overlapping burdens. Patients identified fatigue, dyspnea, and chronic pain as major daily-life impairments; cognitive effects, insomnia, anxiety, depression, cough, and cachexia may also be consequential. fdafdaThe Voice of the Patient Distinguishing disease progression, treatment toxicity, and comorbid cardiopulmonary disease is clinically important because the management and implications for ongoing treatment differ.

Discuss the realistic purpose of each treatment line: cure, reduction of recurrence risk, durable control, symptom relief, or a limited survival gain. Patient priorities vary and can change with disease progression or treatment toxicity; some prioritize prolonging life, while others place equal or greater value on function and symptom burden. fdafdaThe Voice of the Patient

Integrate symptom-directed interventions—oxygen when clinically indicated, analgesia, management of treatment toxicities, rehabilitation or breathing/exercise strategies, and psychosocial care—with disease-directed treatment. fdafdaThe Voice of the Patient The supplied sources do not support a medication-specific palliative dosing protocol.

In a National Cancer Database analysis of 441,812 U.S. patients diagnosed from 2010 through 2014, 62.1% received guideline-concordant first-course treatment; 21.6% received no treatment and 16.3% received less intensive treatment than recommended. PubMedPubMedDisparities in Receiving Guideline-Concordant Treatment for Lung Cancer in the United States - PMC These historical data should not be used as a current benchmark for contemporary drug selection, but they underscore the need for reliable referral pathways and multidisciplinary review.

After adjustment for patient, tumor, and provider characteristics, patients aged 80 years or older and non-Hispanic Black patients were less likely to receive guideline-concordant treatment than patients younger than 50 years and non-Hispanic White patients, respectively. PubMedPubMedDisparities in Receiving Guideline-Concordant Treatment for Lung Cancer in the United States - PMC Do not equate age alone with inability to benefit. Instead, make treatment decisions using physiologic reserve, comorbidity, tumor features, access barriers, and informed patient preference.